Obesity pharmacotherapy: What is next?

Molecular Aspects of Medicine

Volumn 34, Issue 1, 2013, Pages 71-83

  Colon Gonzalez, Francheska ^a   Kim, Gilbert W ^a,b   Lin, Jieru E ^a,b   Valentino, Michael A ^a,b   Waldman, Scott A ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b 1020 Locust St JAH 349 ^*  (United States)

Author keywords

Anti obesity drugs; Appetite; Metabolism; Obesity

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; 2,4 DINITROPHENOL; AMFEPRAMONE; AMINOREX; AMPHETAMINE; AMYLIN; ANTIOBESITY AGENT; CHOLECYSTOKININ; DEXFENFLURAMINE; DIACYLGLYCEROL ACYLTRANSFERASE; DOPAMINE; FENFLURAMINE; GHRELIN; GLUCAGON LIKE PEPTIDE 1; HISTAMINE; LEPTIN; METHIONYL AMINOPEPTIDASE 2; MONOAMINE; NEUROPEPTIDE; NORADRENALIN; OXYNTOMODULIN; PANCREAS HORMONE; PANCREAS POLYPEPTIDE; PEPTIDE YY; PHENTERMINE; PHENYLPROPANOLAMINE; RIMONABANT; SEROTONIN; TRIACYLGLYCEROL LIPASE; UNINDEXED DRUG;

ADIPOSE TISSUE; AGRANULOCYTOSIS; BRAIN HEMORRHAGE; CARDIOTOXICITY; CATARACT; CEREBROVASCULAR ACCIDENT; CHRONIC DISEASE; CLINICAL EFFECTIVENESS; DEPRESSION; DERMATITIS; DRUG APPROVAL; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG MARKETING; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; DRUG WITHDRAWAL; ENZYME INHIBITION; HISTORY OF MEDICINE; HUMAN; HYPERTHERMIA; MONOAMINE RELEASE; NEUROMODULATION; OBESITY; PULMONARY HYPERTENSION; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SIGNAL TRANSDUCTION; SUDDEN DEATH; SUICIDE; TREATMENT DURATION;

ANTI-OBESITY AGENTS; APPETITE; DRUG DELIVERY SYSTEMS; HUMANS; LIFE STYLE; LIPASE; NEUROPEPTIDES; OBESITY; PANCREATIC HORMONES; SYNAPTIC TRANSMISSION; WEIGHT LOSS;

EID: 84872125319     PISSN: 00982997     EISSN: 18729452     Source Type: Journal    
DOI: 10.1016/j.mam.2012.10.005     Document Type: Review

References (142)

1. Counsel on Pharmacy and Chemistry Dinitrophenol not acceptable for N.N.R JAMA 105 1935 31 33
2. T.E. Adrian, S.R. Bloom, M.G. Bryant, J.M. Polak, P.H. Heitz, and A.J. Barnes Distribution and release of human pancreatic polypeptide Gut 17 12 1976 940 944 (Pubitemid 8027537)
3. T.E. Adrian, G.L. Ferri, A.J. Bacarese-Hamilton, H.S. Fuessl, J.M. Polak, and S.R. Bloom Human distribution and release of a putative new gut hormone, peptide YY Gastroenterology 89 5 1985 1070 1077 (Pubitemid 16231572)
4. T.E. Adrian, G.R. Greenberg, H.S. Besterman, and S.R. Bloom Pharmacokinetics of pancreatic polypeptide in man Gut 19 10 1978 907 909 (Pubitemid 9032820)
5. AEterna-Zentaris, 2011. AEterna-Zentaris products in development: AEZS-123 ghrelin receptor antagonist, < http://www.aezsinc.com/en/page.php?p= 32&prod=28 > (June 21, 2011).
6. R.S. Ahima, D. Prabakaran, C. Mantzoros, D. Qu, B. Lowell, E. Maratos-Flier, and J.S. Flier Role of leptin in the neuroendocrine response to fasting Nature 382 6588 1996 250 252 (Pubitemid 26251358)
7. R.E. Amori, J. Lau, and A.G. Pittas Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis JAMA 298 2 2007 194 206 (Pubitemid 47057766)
8. AMRI, 2011. Obesity-MCH-1 antagonists, < http://www.amriglobal.com/ pipeline/subpage.cfm?ID=17&subID=69 > (June 25, 2011).
9. Amylin, 2009. Amylin pharmaceuticals announces positive results from dose-ranging clinical study of pramlintide/metreleptin combination treatment for obesity, < http://phx.corporate-ir.net/phoenix.zhtml?c=101911&p=irol- newsArticle&ID=1305954&highlight=metreleptin > (July 1, 2011).
10. Amylin, 2010. Amylin and takeda announce decision to advance development of pramlintide/metreleptin combination treatment for obesity, < http://phx.corporate-ir.net/phoenix.zhtml?c=101911&p=irol- newsArticle&ID=1393827&highlight=metreleptin > (July 1, 2011).
11. Amylin, 2011. Amylin and takeda voluntarily suspend clinical activities in obesity trial, < http://phx.corporate-ir.net/phoenix.zhtml?c=101911&p= irol-newsArticle&ID=1539763&highlight=metreleptin > (June 29, 2011).
12. Andrade, S.M., Couselo Carreira, M., Ribeiro, A., Teixeira, L., Monteiro, D., Lage, M., Casanueva, F., Monteiro, M.P., 2011. In: Development of an Anti-Ghrelin Vaccine for Obesity Treatment The Endocrine Society's 93rd Annual Meeting. Endocrine Reviews, Boston, pp. P2-305.
13. Arena, 2010. FDA issues complete response letter for lorcaserin new drug application, < http://invest.arenapharm.com/releasedetail.cfm?ReleaseID= 521977 > (July 1, 2011).
14. A. Asakawa, A. Inui, H. Yuzuriha, N. Ueno, G. Katsuura, M. Fujimiya, M.A. Fujino, A. Niijima, M.M. Meguid, and M. Kasuga Characterization of the effects of pancreatic polypeptide in the regulation of energy balance Gastroenterology 124 5 2003 1325 1336 (Pubitemid 36531807)
15. W.L. Asher Mortality rate in patients receiving "diet pills" Current Therapeutic Research, Clinical and Experimental 14 8 1972 525 539
16. A. Astrup, S. Madsbad, L. Breum, T.J. Jensen, J.P. Kroustrup, and T.M. Larsen Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: A randomised, double-blind, placebo-controlled trial Lancet 372 9653 2008 1906 1913
17. R.L. Batterham, M.A. Cohen, S.M. Ellis, C.W. Le Roux, D.J. Withers, G.S. Frost, M.A. Ghatei, and S.R. Bloom Inhibition of food intake in obese subjects by peptide YY3-36 The New England Journal of Medicine 349 10 2003 941 948 (Pubitemid 37064767)
18. R.L. Batterham, M.A. Cowley, C.J. Small, H. Herzog, M.A. Cohen, C.L. Dakin, A.M. Wren, A.E. Brynes, M.J. Low, M.A. Ghatei, R.D. Cone, and S.R. Bloom Gut hormone PYY(3-36) physiologically inhibits food intake Nature 418 6898 2002 650 654
19. R.L. Batterham, C.W. Le Roux, M.A. Cohen, A.J. Park, S.M. Ellis, M. Patterson, G.S. Frost, M.A. Ghatei, and S.R. Bloom Pancreatic polypeptide reduces appetite and food intake in humans The Journal of Clinical Endocrinology and Metabolism 88 8 2003 3989 3992 (Pubitemid 37034556)
20. B. Beck, and S. Richy Dietary modulation of ghrelin and leptin and gorging behavior after weight loss in the obese Zucker rat The Journal of Endocrinology 202 1 2009 29 34
21. C. Beglinger, L. Degen, D. Matzinger, M. D'Amato, and J. Drewe Loxiglumide, a CCK-A receptor antagonist, stimulates calorie intake and hunger feelings in humans American Journal of Physiology 280 4 2001 R1149 R1154
22. S. Bhasin, W. Wallace, J.B. Lawrence, and M. Lesch Sudden death associated with thyroid hormone abuse The American Journal of Medicine 71 5 1981 887 890 (Pubitemid 12192368)
23. BMS, 2011. Bristol-myers squibb clinical trials registry metabolics, < http://ctr.bms.com/OneBmsCtd/InitTrialDetailAction.do?pnum=MB123-002 > (June 18, 2011).
24. V.P. Carlini, M.M. Varas, A.B. Cragnolini, H.B. Schioth, T.N. Scimonelli, and S.R. de Barioglio Differential role of the hippocampus, amygdala, and dorsal raphe nucleus in regulating feeding, memory, and anxiety-like behavioral responses to ghrelin Biochemical and Biophysical Research Communications 313 3 2004 635 641 (Pubitemid 38021878)
25. CDC, 2011. CDC: economics consequences of overweight and obesity, < http://www.cdc.gov/obesity/causes/economics.html > (June 17, 2011).
26. O. Chaudhri, C. Small, and S. Bloom Gastrointestinal hormones regulating appetite Philosophical Transactions of the Royal Society of London 361 1471 2006 1187 1209 (Pubitemid 44874228)
27. H.M. Connolly, J.L. Crary, M.D. McGoon, D.D. Hensrud, B.S. Edwards, W.D. Edwards, and H.V. Schaff Valvular heart disease associated with fenfluramine-phentermine The New England Journal of Medicine 337 9 1997 581 588 (Pubitemid 27360757)
28. R.V. Considine, M.K. Sinha, M.L. Heiman, A. Kriauciunas, T.W. Stephens, M.R. Nyce, J.P. Ohannesian, C.C. Marco, L.J. McKee, and T.L. Bauer Serum immunoreactive-leptin concentrations in normal-weight and obese humans The New England Journal of Medicine 334 5 1996 292 295 (Pubitemid 26033933)
29. J.N. Crawley, and M.C. Beinfeld Rapid development of tolerance to the behavioural actions of cholecystokinin Nature 302 5910 1983 703 706 (Pubitemid 13120271)
30. J.N. Crawley, and R.L. Corwin Biological actions of cholecystokinin Peptides 15 4 1994 731 755 (Pubitemid 24221851)
31. Cytos, 2006. Phase I/IIa clinical trial with obese individuals shows no effect of CYT009-GhrQb on weight loss, < http://www.cytos.com/doc/Cytos- Press-E-061107.pdf > (July 1, 2011).
32. Y. Date, N. Murakami, K. Toshinai, S. Matsukura, A. Niijima, H. Matsuo, K. Kangawa, and M. Nakazato The role of the gastric afferent vagal nerve in ghrelin-induced feeding and growth hormone secretion in rats Gastroenterology 123 4 2002 1120 1128
33. B. Datta Roles of P67/MetAP2 as a tumor suppressor Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1796 2 2009 281 292
34. L. Degen, S. Oesch, M. Casanova, S. Graf, S. Ketterer, J. Drewe, and C. Beglinger Effect of peptide YY3-36 on food intake in humans Gastroenterology 129 5 2005 1430 1436 (Pubitemid 41597385)
35. D.J. Drucker The biology of incretin hormones Cell Metabolism 3 3 2006 153 165
36. S.V. Edelman, and C. Weyer Unresolved challenges with insulin therapy in type 1 and type 2 diabetes: potential benefit of replacing amylin, a second beta-cell hormone Diabetes Technology and Therapeutics 4 2 2002 175 189 (Pubitemid 34663480)
37. G.L. Edwards, B.R. Gedulin, C. Jodka, R.P. Dilts, C.C. Miller, and A. Young Area postrema (AP)-lessions block the regulation of gastric emptying by amylin Neurogastroenterology Motility 10 4 1998 26
38. Emisphere, 2011. Oral GLP-1, for type 2 diabetes, < http://www.emisphere.com/oral-GLP-1.html > (June 21, 2011).
39. N. Erondu, I. Gantz, B. Musser, S. Suryawanshi, M. Mallick, C. Addy, J. Cote, G. Bray, K. Fujioka, H. Bays, P. Hollander, S.M. Sanabria-Bohorquez, W. Eng, B. Langstrom, R.J. Hargreaves, H.D. Burns, A. Kanatani, T. Fukami, D.J. MacNeil, K.M. Gottesdiener, J.M. Amatruda, K.D. Kaufman, and S.B. Heymsfield Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults Cell Metabolism 4 4 2006 275 282 (Pubitemid 44430911)
40. W.K. Fakhoury, C. Lereun, and D. Wright A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes Pharmacology 86 1 2010 44 57
41. I.S. Farooqi, and S. O'Rahilly Monogenic obesity in humans Annual Review of Medicine 56 2005 443 458 (Pubitemid 40299792)
42. FDA, 2005. Phenylpropanolamine (PPA) information page, < http://www.fda.gov/drugs/drugsafety/informationbydrugclass/ucm150738.htm > (June 7, 2011).
43. FDA, 2007. Guidance for industry developing products for weight management, < http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm071612.pdf > (July 1, 2011).
44. K.M. Flegal, M.D. Carroll, C.L. Ogden, and L.R. Curtin Prevalence and trends in obesity among US adults, 1999-2008 JAMA 303 3 2010 235 241
45. A. Flint, A. Raben, A. Astrup, and J.J. Holst Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans The Journal of Clinical Investigation 101 3 1998 515 520 (Pubitemid 28084232)
46. T.M. Fong Advances in anti-obesity therapeutics Expert Opinion on Investigational Drugs 14 3 2005 243 250 (Pubitemid 40520964)
47. S. Fujimoto, A. Inui, N. Kiyota, W. Seki, K. Koide, S. Takamiya, M. Uemoto, Y. Nakajima, S. Baba, and M. Kasuga Increased cholecystokinin and pancreatic polypeptide responses to a fat-rich meal in patients with restrictive but not bulimic anorexia nervosa Biological Psychiatry 41 10 1997 1068 1070 (Pubitemid 27225995)
48. I. Gantz, N. Erondu, M. Mallick, B. Musser, R. Krishna, W.K. Tanaka, K. Snyder, C. Stevens, M.A. Stroh, H. Zhu, J.A. Wagner, D.J. Macneil, S.B. Heymsfield, and J.M. Amatruda Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults The Journal of Clinical Endocrinology and Metabolism 92 5 2007 1754 1757 (Pubitemid 46997183)
49. F.L. Greenway, M.J. Whitehouse, M. Guttadauria, J.W. Anderson, R.L. Atkinson, K. Fujioka, K.M. Gadde, A.K. Gupta, P. O'Neil, D. Schumacher, D. Smith, E. Dunayevich, G.D. Tollefson, E. Weber, and M.A. Cowley Rational design of a combination medication for the treatment of obesity Obesity 17 1 2009 30 39 (Pubitemid 50324544)
50. GSK, 2011. GlaxoSmithKline announces non-core OTC products to be divested, < http://www.gsk.com/media/pressreleases/2011/2011-pressrelease- 402902.htm > (June 7, 2011).
51. H.P. Gurtner Aminorex and pulmonary hypertension: A review Cor et vasa 27 2-3 1985 160 171
52. C.A. Haller, and N.L. Benowitz Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids The New England Journal of Medicine 343 25 2000 1833 1838 (Pubitemid 32104128)
53. A.A. Hancock, Y.L. Bennani, E.N. Bush, T.A. Esbenshade, R. Faghih, G.B. Fox, P. Jacobson, V. Knourek-Segel, K.M. Krueger, M.E. Nuss, J.B. Pan, R. Shapiro, D.G. Witte, and B.B. Yao Antiobesity effects of A-331440, a novel non-imidazole histamine H3 receptor antagonist European Journal of Pharmacology 487 1-3 2004 183 197 (Pubitemid 38368996)
54. P.A. Hollander, P. Levy, M.S. Fineman, D.G. Maggs, L.Z. Shen, S.A. Strobel, C. Weyer, and O.G. Kolterman Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: A 1-year randomized controlled trial Diabetes Care 26 3 2003 784 790 (Pubitemid 36929344)
55. Y. Hort, E. Baker, G.R. Sutherland, J. Shine, and H. Herzog Gene duplication of the human peptide YY gene (PYY) generated the pancreatic polypeptide gene (PPY) on chromosome 17q21.1 Genomics 26 1 1995 77 83
56. A.M. Ingalls, M.M. Dickie, and G.D. Snell Obese, a new mutation in the house mouse Obesity Research 4 1 1996 101
57. C. Jodka, D. Green, A. Young, and B. Gedulin Amylin modulation of gastric emptying in rats depends upon an intact vagus nerve Diabetes 45 Suppl. 1 1996
58. A. Kanatani, S. Mashiko, N. Murai, N. Sugimoto, J. Ito, T. Fukuroda, T. Fukami, N. Morin, D.J. MacNeil, L.H. Van der Ploeg, Y. Saga, S. Nishimura, and M. Ihara Role of the Y1 receptor in the regulation of neuropeptide Y-mediated feeding: comparison of wild-type, Y1 receptor-deficient, and Y5 receptor-deficient mice Endocrinology 141 3 2000 1011 1016 (Pubitemid 32260445)
59. E. Karra, A. Yousseif, and R.L. Batterham Mechanisms facilitating weight loss and resolution of type 2 diabetes following bariatric surgery Trends in Endocrinology and Metabolism 21 6 2010 337 344
60. W.N. Kernan, C.M. Viscoli, L.M. Brass, J.P. Broderick, T. Brott, E. Feldmann, L.B. Morgenstern, J.L. Wilterdink, and R.I. Horwitz Phenylpropanolamine and the risk of hemorrhagic stroke The New England Journal of Medicine 343 25 2000 1826 1832 (Pubitemid 32104127)
61. J.E. Koda, M. Fineman, T.J. Rink, G.E. Dailey, D.B. Muchmore, and L.G. Linarelli Amylin concentrations and glucose control Lancet 339 8802 1992 1179 1180
62. J.E. Koda, M.S. Fineman, O.G. Kolterman, and J.F. Caro 24 hour plasma amylin profiles are elevated in IGT subjects vs normal controls Diabetes Suppl. 1 1995
63. M. Kojima, H. Hosoda, Y. Date, M. Nakazato, H. Matsuo, and K. Kangawa Ghrelin is a growth-hormone-releasing acylated peptide from stomach Nature 402 6762 1999 656 660 (Pubitemid 129516334)
64. P. Kopelman, A. Bryson, R. Hickling, A. Rissanen, S. Rossner, S. Toubro, and P. Valensi Cetilistat (ATL-962), a novel lipase inhibitor: A 12-week randomized, placebo-controlled study of weight reduction in obese patients International Journal of Obesity 31 3 2007 494 499
65. R. Krishna, B. Gumbiner, C. Stevens, B. Musser, M. Mallick, S. Suryawanshi, L. Maganti, H. Zhu, T.H. Han, L. Scherer, B. Simpson, D. Cosgrove, K. Gottesdiener, J. Amatruda, B.J. Rolls, J. Blundell, G.A. Bray, K. Fujioka, S.B. Heymsfield, J.A. Wagner, and G.A. Herman Potent and selective agonism of the melanocortin receptor 4 with MK-0493 does not induce weight loss in obese human subjects: energy intake predicts lack of weight loss efficacy Clinical Pharmacology and Therapeutics 86 6 2009 659 666
66. D. Larhammar Structural diversity of receptors for neuropeptide Y, peptide YY and pancreatic polypeptide Regulatory Peptides 65 3 1996 165 174 (Pubitemid 26325603)
67. C.W. le Roux, R.L. Batterham, S.J. Aylwin, M. Patterson, C.M. Borg, K.J. Wynne, A. Kent, R.P. Vincent, J. Gardiner, M.A. Ghatei, and S.R. Bloom Attenuated peptide YY release in obese subjects is associated with reduced satiety Endocrinology 147 1 2006 3 8 (Pubitemid 43004254)
68. H.R. Lijnen, L. Frederix, and B. Van Hoef Fumagillin reduces adipose tissue formation in murine models of nutritionally induced obesity Obesity 18 12 2010 2241 2246
69. C.D. Liu, T. Aloia, T.E. Adrian, T.R. Newton, A.J. Bilchik, M.J. Zinner, S.W. Ashley, and D.W. McFadden Peptide YY: A potential proabsorptive hormone for the treatment of malabsorptive disorders The American Surgeon 62 3 1996 232 236 (Pubitemid 26158136)
70. L. Lukaszewski, and M. Praissman Effect of continuous infusions of CCK-8 on food intake and body and pancreatic weights in rats The American Journal of Physiology 254 1 Pt. 2 1988 R17 R22
71. T.A. Lutz, A. Mollet, P.A. Rushing, T. Riediger, and E. Scharrer The anorectic effect of a chronic peripheral infusion of amylin is abolished in area postrema/nucleus of the solitary tract (AP/NTS) lesioned rats International Journal of Obesity and Related Metabolic Disorders 25 7 2001 1005 1011 (Pubitemid 32566055)
72. D. Maggs, L. Shen, S. Strobel, D. Brown, O. Kolterman, and C. Weyer Effect of pramlintide on A1C and body weight in insulin-treated African Americans and Hispanics with type 2 diabetes: A pooled post hoc analysis Metabolism Clinical and Experimental 52 12 2003 1638 1642 (Pubitemid 38049286)
73. F. Malaisse-Lagae, J.L. Carpentier, Y.C. Patel, W.J. Malaisse, and L. Orci Pancreatic polypeptide: A possible role in the regulation of food intake in the mouse hypothesis Experientia 33 7 1977 915 917 (Pubitemid 8128835)
74. T. Masaki, S. Chiba, G. Yoshimichi, T. Yasuda, H. Noguchi, T. Kakuma, T. Sakata, and H. Yoshimatsu Neuronal histamine regulates food intake, adiposity, and uncoupling protein expression in agouti yellow (A(y)/a) obese mice Endocrinology 144 6 2003 2741 2748 (Pubitemid 36629927)
75. S. Mashiko, R. Moriya, A. Ishihara, A. Gomori, H. Matsushita, S. Egashira, H. Iwaasa, T. Takahashi, Y. Haga, T. Fukami, and A. Kanatani Synergistic interaction between neuropeptide Y1 and Y5 receptor pathways in regulation of energy homeostasis European Journal of Pharmacology 615 1-3 2009 113 117
76. H. Masuzaki, J. Paterson, H. Shinyama, N.M. Morton, J.J. Mullins, J.R. Seckl, and J.S. Flier A transgenic model of visceral obesity and the metabolic syndrome Science 294 5549 2001 2166 2170 (Pubitemid 33150673)
77. C.A. Matson, and R.C. Ritter Long-term CCK-leptin synergy suggests a role for CCK in the regulation of body weight The American Journal of Physiology 276 4 Pt. 2 1999 R1038 R1045
78. K. Meeran, D. O'Shea, C.M. Edwards, M.D. Turton, M.M. Heath, I. Gunn, S. Abusnana, M. Rossi, C.J. Small, A.P. Goldstone, G.M. Taylor, D. Sunter, J. Steere, S.J. Choi, M.A. Ghatei, and S.R. Bloom Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat Endocrinology 140 1 1999 244 250 (Pubitemid 29011165)
79. R. Mentlein, B. Gallwitz, and W.E. Schmidt Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum European Journal of Biochemistry/FEBS 214 3 1993 829 835 (Pubitemid 23188160)
80. C.T. Montague, I.S. Farooqi, J.P. Whitehead, M.A. Soos, H. Rau, N.J. Wareham, C.P. Sewter, J.E. Digby, S.N. Mohammed, J.A. Hurst, C.H. Cheetham, A.R. Earley, A.H. Barnett, J.B. Prins, and S. O'Rahilly Congenital leptin deficiency is associated with severe early-onset obesity in humans Nature 387 6636 1997 903 908 (Pubitemid 27289591)
81. T.H. Moran Cholecystokinin and satiety: current perspectives Nutrition 16 10 2000 858 865
82. T.H. Moran, A.R. Baldessarini, C.F. Salorio, T. Lowery, and G.J. Schwartz Vagal afferent and efferent contributions to the inhibition of food intake by cholecystokinin The American Journal of Physiology 272 4 Pt. 2 1997 R1245 R1251
83. T.H. Moran, and S. Bi Hyperphagia and obesity in OLETF rats lacking CCK-1 receptors Philosophical Transactions of the Royal Society of London 361 1471 2006 1211 1218 (Pubitemid 44874229)
84. T.H. Moran, and M.J. Dailey Minireview: gut peptides: targets for antiobesity drug development? Endocrinology 150 6 2009 2526 2530
85. T.H. Moran, L. Shnayder, A.M. Hostetler, and P.R. McHugh Pylorectomy reduces the satiety action of cholecystokinin The American Journal of Physiology 255 6 Pt. 2 1988 R1059 R1063
86. M.G. Myers Jr. Leptin receptor signaling and the regulation of mammalian physiology Recent Progress in Hormone Research 59 2004 287 304
87. A.M. Naleid, M.K. Grace, D.E. Cummings, and A.S. Levine Ghrelin induces feeding in the mesolimbic reward pathway between the ventral tegmental area and the nucleus accumbens Peptides 26 11 2005 2274 2279 (Pubitemid 41584095)
88. E. Naslund, N. King, S. Mansten, N. Adner, J.J. Holst, M. Gutniak, and P.M. Hellstrom Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects The British Journal of Nutrition 91 3 2004 439 446 (Pubitemid 38386908)
89. NeuroSearch, 2011. NeuroSearch reports on scientific advice received from the FDA and EMA concerning the clinical development programme for tesofensine, < http://www.neurosearch.dk/Default.aspx?ID=16&M=News&PID= 12&NewsID=16083 > (June 22, 2011).
90. K. Nonogaki, A.M. Strack, M.F. Dallman, and L.H. Tecott Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene Nature Medicine 4 10 1998 1152 1156 (Pubitemid 28468828)
91. Orexigen, 2009. Orexigen(R) therapeutics phase 2b Trial for Empatic(TM) meets primary efficacy endpoint demonstrating significantly greater weight loss versus comparators in obese, < http://ir.orexigen.com/phoenix.zhtml?c= 207034&p=irol-newsArticle&ID=1336796&highlight= > (June 22, 2011).
92. Orexigen, 2010. Orexigen(R) therapeutics announces publication of COR-I Phase 3 Study of Contrave in Lancet, < http://ir.orexigen.com/phoenix.zhtml? c=207034&p=irol-newsArticle&ID=1454172&highlight= > (July 1, 2011).
93. Orexigen, 2011. FDA issues complete response to new drug application for Contrave(R) for the management of obesity, < http://ir.orexigen.com/phoenix. zhtml?c=207034&p=irol-newsArticle&ID=1522207&highlight= > (July 1, 2011).
94. A.A. Ortiz, L.F. Milardo, L.B. DeCarr, T.M. Buckholz, M.R. Mays, T.H. Claus, J.N. Livingston, C.D. Mahle, and K.J. Lumb A novel long-acting selective neuropeptide Y2 receptor polyethylene glycol-conjugated peptide agonist reduces food intake and body weight and improves glucose metabolism in rodents The Journal of Pharmacology and Experimental Therapeutics 323 2 2007 692 700 (Pubitemid 350005120)
95. B. Otto, U. Cuntz, E. Fruehauf, R. Wawarta, C. Folwaczny, R.L. Riepl, M.L. Heiman, P. Lehnert, M. Fichter, and M. Tschop Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa European Journal of Endocrinology/European Federation of Endocrine Societies 145 5 2001 669 673
96. L. Ozcan, A.S. Ergin, A. Lu, J. Chung, S. Sarkar, D. Nie, M.G. Myers Jr., and U. Ozcan Endoplasmic reticulum stress plays a central role in development of leptin resistance Cell Metabolism 9 1 2009 35 51
97. S.J. Pandol, S. Periskic, I. Gukovsky, V. Zaninovic, Y. Jung, Y. Zong, T.E. Solomon, A.S. Gukovskaya, and H. Tsukamoto Ethanol diet increases the sensitivity of rats to pancreatitis induced by cholecystokinin octapeptide Gastroenterology 117 3 1999 706 716 (Pubitemid 29409258)
98. O.J. Phung, J.M. Scholle, M. Talwar, and C.I. Coleman Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes JAMA 303 14 2010 1410 1418
99. R.A. Pittner, K. Albrandt, K. Beaumont, L.S. Gaeta, J.E. Koda, C.X. Moore, J. Rittenhouse, and T.J. Rink Molecular physiology of amylin Journal of Cellular Biochemistry 55 Suppl. 19-28 1994
100. T. Plusczyk, S. Westermann, D. Rathgeb, and G. Feifel Acute pancreatitis in rats: effects of sodium taurocholate, CCK-8, and Sec on pancreatic microcirculation The American Journal of Physiology 272 2 Pt. 1 1997 G310 G320
101. R.E. Pratley Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes Medscape Journal of Medicine 10 7 2008 171
102. PROLOR-Biotech, 2011. PROLOR biotech reports positive preclinical results in weight loss study of its long-acting anti-obesity drug candidate, < http://www.prolor-biotech.com/?CategoryID=211&ArticleID=99&sng=1 > (June 18, 2011).
103. Public-Citizen, 2011. Public citizen: petition to FDA to ban Orlistat, < http://citizen.org/petition-to-fda-to-ban-orlistat-alli-xenical-2011 > (June 7, 2011).
104. R.E. Ratner, L.L. Want, M.S. Fineman, M.J. Velte, J.A. Ruggles, A. Gottlieb, C. Weyer, and O.G. Kolterman Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes Diabetes Technology and Therapeutics 4 1 2002 51 61 (Pubitemid 34441520)
105. E. Ravussin, S.R. Smith, J.A. Mitchell, R. Shringarpure, K. Shan, H. Maier, J.E. Koda, and C. Weyer Enhanced weight loss with pramlintide/ metreleptin: An integrated neurohormonal approach to obesity pharmacotherapy Obesity 17 9 2009 1736 1743
106. T. Reinehr, P.J. Enriori, K. Harz, M.A. Cowley, and C.L. Roth Pancreatic polypeptide in obese children before and after weight loss International Journal of Obesity 30 10 2006 1476 1481 (Pubitemid 44470194)
107. Rhythm, 2011. RM-493: MC4R Peptide Therapeutic. A new drug class for the treatment of obesity and diabetes, < http://www.rhythmtx.com/PROGRAMS/RM493. html > (June 25, 2011).
108. J.D. Roth, B.L. Roland, R.L. Cole, J.L. Trevaskis, C. Weyer, J.E. Koda, C.M. Anderson, D.G. Parkes, and A.D. Baron Leptin responsiveness restored by amylin agonism in diet-induced obesity: evidence from nonclinical and clinical studies Proceedings of the National Academy of Sciences of the United States of America 105 20 2008 7257 7262 (Pubitemid 351754465)
109. P.A. Rushing, M.M. Hagan, R.J. Seeley, T.A. Lutz, and S.C. Woods Amylin: A novel action in the brain to reduce body weight Endocrinology 141 2 2000 850 853 (Pubitemid 32250511)
110. B.J. Sargent, and N.A. Moore New central targets for the treatment of obesity British Journal of Clinical Pharmacology 68 6 2009 852 860
111. M.W. Schwartz, D.G. Baskin, T.R. Bukowski, J.L. Kuijper, D. Foster, G. Lasser, D.E. Prunkard, D. Porte Jr., S.C. Woods, R.J. Seeley, and D.S. Weigle Specificity of leptin action on elevated blood glucose levels and hypothalamic neuropeptide Y gene expression in ob/ob mice Diabetes 45 4 1996 531 535 (Pubitemid 26111317)
112. M.W. Schwartz, R.J. Seeley, S.C. Woods, D.S. Weigle, L.A. Campfield, P. Burn, and D.G. Baskin Leptin increases hypothalamic pro-opiomelanocortin mRNA expression in the rostral arcuate nucleus Diabetes 46 12 1997 2119 2123 (Pubitemid 27512108)
113. M.W. Schwartz, S.C. Woods, D. Porte Jr., R.J. Seeley, and D.G. Baskin Central nervous system control of food intake Nature 404 6778 2000 661 671 (Pubitemid 30205071)
114. Shionogi, 2009. Shionogi announces positive top-line efficacy results from year-long studies of velneperit, a novel NPY Y5 receptor antagonist being investigated for the treatment of obesity, < http://www.shionogiusa.com/news/ press/News2009.html > (June 22, 2011).
115. A. Sjodin, C. Gasteyger, A.L. Nielsen, A. Raben, J.D. Mikkelsen, J.K. Jensen, D. Meier, and A. Astrup The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men International Journal of Obesity 34 11 2010 1634 1643
116. S.J. Smith, S. Cases, D.R. Jensen, H.C. Chen, E. Sande, B. Tow, D.A. Sanan, J. Raber, R.H. Eckel, and R.V. Farese Jr. Obesity resistance and multiple mechanisms of triglyceride synthesis in mice lacking Dgat Nature Genetics 25 1 2000 87 90 (Pubitemid 30257043)
117. R.E. Steinert, B. Poller, M.C. Castelli, J. Drewe, and C. Beglinger Oral administration of glucagon-like peptide 1 or peptide YY 3-36 affects food intake in healthy male subjects The American Journal of Clinical Nutrition 92 4 2010 810 817
118. T.W. Stephens, M. Basinski, P.K. Bristow, J.M. Bue-Valleskey, S.G. Burgett, L. Craft, J. Hale, J. Hoffmann, H.M. Hsiung, and A. Kriauciunas The role of neuropeptide Y in the antiobesity action of the obese gene product Nature 377 6549 1995 530 532
119. Y. Sun, S. Ahmed, and R.G. Smith Deletion of ghrelin impairs neither growth nor appetite Molecular and Cellular Biology 23 22 2003 7973 7981 (Pubitemid 37377491)
120. Y.X. Tao The melanocortin-4 receptor: physiology, pharmacology, and pathophysiology Endocrine Reviews 31 4 2010 506 543
121. V. Tolle, M. Kadem, M.T. Bluet-Pajot, D. Frere, C. Foulon, C. Bossu, R. Dardennes, C. Mounier, P. Zizzari, F. Lang, J. Epelbaum, and B. Estour Balance in ghrelin and leptin plasma levels in anorexia nervosa patients and constitutionally thin women The Journal of Clinical Endocrinology and Metabolism 88 1 2003 109 116 (Pubitemid 36115151)
122. TransTech-Pharma, 2011. TTP-435, < http://www.ttpharma.com/ TherapeuticAreas/MetabolicDiseases/Obesity/TTP435/tabid/126/Default.aspx > (June 17, 2011).
123. M. Tschop, C. Weyer, P.A. Tataranni, V. Devanarayan, E. Ravussin, and M.L. Heiman Circulating ghrelin levels are decreased in human obesity Diabetes 50 4 2001 707 709 (Pubitemid 32242624)
124. M.D. Turton, D. O'Shea, I. Gunn, S.A. Beak, C.M. Edwards, K. Meeran, S.J. Choi, G.M. Taylor, M.M. Heath, P.D. Lambert, J.P. Wilding, D.M. Smith, M.A. Ghatei, J. Herbert, and S.R. Bloom A role for glucagon-like peptide-1 in the central regulation of feeding Nature 379 6560 1996 69 72 (Pubitemid 26008136)
125. Vivus, 2010. FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA(R), < http://ir.vivus.com/releasedetail.cfm? ReleaseID=524576 > (July 1, 2011).
126. G.-J. Wang, A. Geliebter, N.D. Volkow, F.W. Telang, J. Logan, M.C. Jayne, K. Galanti, P.A. Selig, H. Han, W. Zhu, C.T. Wong, and J.S. Fowler Enhanced striatal dopamine release during food stimulation in binge eating disorder Obesity 2011
127. Week, B.B., 2011. Elixir Pharmaceuticals, Inc., < http://investing. businessweek.com/research/stocks/private/snapshot.asp?privcapId=2246762 > (June 29, 2011).
128. M.A. Weir, M.M. Beyea, T. Gomes, D.N. Juurlink, M. Mamdani, P.G. Blake, R. Wald, and A.X. Garg Orlistat and acute kidney injury: An analysis of 953 patients Archives of Internal Medicine 171 7 2011 703 704
129. D.B. West, D. Fey, and S.C. Woods Cholecystokinin persistently suppresses meal size but not food intake in free-feeding rats The American Journal of Physiology 246 5 Pt 2 1984 R776 R787
130. F. Whitehouse, D.F. Kruger, M. Fineman, L. Shen, J.A. Ruggles, D.G. Maggs, C. Weyer, and O.G. Kolterman A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes Diabetes Care 25 4 2002 724 730 (Pubitemid 41071194)
131. WHO, 2011. Obesity and overweight: key facts, < http://www.who.int/ mediacentre/factsheets/fs311/en/index.html > (June 29, 2011).
132. J.E. Wikberg, and F. Mutulis Targeting melanocortin receptors: An approach to treat weight disorders and sexual dysfunction Nature Reviews 7 4 2008 307 323
133. K. Wynne, A.J. Park, C.J. Small, K. Meeran, M.A. Ghatei, G.S. Frost, and S.R. Bloom Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: A randomised controlled trial International Journal of Obesity 30 12 2006 1729 1736 (Pubitemid 44863404)
134. T. Yamamoto, H. Yamaguchi, H. Miki, S. Kitamura, Y. Nakada, T.D. Aicher, S.A. Pratt, and K. Kato A novel coenzyme A: diacylglycerol acyltransferase 1 inhibitor stimulates lipid metabolism in muscle and lowers weight in animal models of obesity European Journal of Pharmacology 650 2-3 2011 663 672
135. J. Yang, T.J. Zhao, J.L. Goldstein, and M.S. Brown Inhibition of ghrelin O-acyltransferase (GOAT) by octanoylated pentapeptides Proceedings of the National Academy of Sciences of the United States of America 105 31 2008 10750 10755
136. R. Yoshimoto, Y. Miyamoto, K. Shimamura, A. Ishihara, K. Takahashi, H. Kotani, A.S. Chen, H.Y. Chen, D.J. MacNeil, A. Kanatani, and S. Tokita Therapeutic potential of histamine H3 receptor agonist for the treatment of obesity and diabetes mellitus Proceedings of the National Academy of Sciences 103 37 2006 13866 13871 (Pubitemid 44413999)
137. Young, A., Moore, C., Herich, J., Beaumont, K., 2000. Neuroendocrine actions of amylin, The CGRP Family: Calcitonin Gene-Related Peptide (CGRP), Amylin, and Adrenomedullin, pp. 91-102.
138. A. Young, W. Vine, and B.R. Gedulin Preclinical pharmacology of pramlintide in the rat: comparisons with human and rat amylin Drug Development Research 37 4 1996 231 248 (Pubitemid 26233319)
139. Zafgen, 2011. Zafgen announces positive topline Phase 1b data for ZGN-433 in obesity, < http://www.zafgen.com/news.html > (June 28, 2011).
140. E.P. Zorrilla, S. Iwasaki, J.A. Moss, J. Chang, J. Otsuji, K. Inoue, M.M. Meijler, and K.D. Janda Vaccination against weight gain Proceedings of the National Academy of Sciences of the United States of America 103 35 2006 13226 13231 (Pubitemid 44338944)
141. 7TM-Pharma, 2011a. Obinepitide, < http://www.7tm.com/R-D/Metabolic- Disorders/Obinepitide.aspx > (June 29, 2011).
142. 7TM-Pharma, 2011b. TM30339, < http://www.7tm.com/R-D/Metabolic- Disorders/TM30339.aspx > (June 29, 2011).